Other strategies to inhibit the NKG2A/HLA-E axis are based on NKG2A downregulation in NK cells by dasatinib (188), or the reduction of HLA-E levels in tumor cells, by drugs such as bortezomib, dinaciclib or selinexor, tested in vitro on MM, AML, and lymphoma, respectively (189–191). Here, KLRC1 is linked to Miyoshi myopathy.